Clinical-stage biotech developing fast-acting psychedelic-derived (5-MeO-DMT) treatments for treatment-resistant depression.
Clinical-stage biotech developing fast-acting psychedelic-derived (5-MeO-DMT) treatments for treatment-resistant depression.
Has no medicine on sale, so it funds trials from money raised from investors, and revenue would arrive only after approval or a licensing deal. The business rests on one lead drug in one form of depression, so trial results move the whole company.
Moat: none (IP / patents). Pre-commercial; must navigate a novel regulatory path for a psychedelic-derived psychiatric drug.
Headquarters: Dublin, Ireland · Founded: 2018 · Employees: 73
Size GH Research (GHRS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.25B, the 2091st largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.25 on 18 Nov 2026.
Performance Over six months the shares fell 19.0%, against -15.6% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.
Short interest Short interest is 3.0% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$359,000 | -$335,000 | -$315,000 | -$315,000 | -$47,000 |
| EBITDA | -$71.1M | -$60.3M | -$49.9M | -$40.9M | -$30.5M |
| Net income | -$62.3M | -$48.3M | -$39.0M | -$35.6M | -$22.5M |
| Free cash flow | -$52.5M | -$43.7M | -$42.3M | -$33.4M | -$26.3M |
| Capital expenditure | $139,151 | $121,000 | $49,000 | $100,000 | $67,000 |
| Total debt | $360,000 | $512,000 | $624,000 | $974,000 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| GH Research GHRS | $1.25B | -19% | n/a | n/a | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | $1.15B | -25% | n/a | n/a | n/a | n/a |
| AtaiBeckley ATAI | n/a | +81% | n/a | n/a | n/a | n/a |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 6.9× | 3.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GHRS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.8% | -5.1% | 9th highest of 20 |
| 6-month return | -19.0% | -15.6% | 9th lowest of 20 |
| Distance from 52-week high | -42.0% | -37.5% | 9th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 4.8× | 3.4% | +27.9% |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 39.1× | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 0.5× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 2.3× | 2.5% | +15.5% |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 2.0× | -0.4% | -1.3% |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 1.8× | 7.0% | -5.3% |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | 10.4× | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | 818.8× | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 12.8× | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 4.7× | n/a | n/a |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | 17.0× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | 10.4× | 44.1% | -13.2% |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | 17.0× | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 2.2× | -17.2% | +3.9% |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 4.0× | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.20B | -29% | +21% | -127% | 13.6× | n/a | n/a |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |